Influence of CA 15-3 blood level and doubling time on diagnostic performances of F-FDG PET in breast cancer patients with occult recurrence

Nuclear Medicine Communications

Volumn 28, Issue 4, 2007, Pages 267-272

  Aide, Nicolas ^a   Huchet, Virginie ^a   Switsers, Odile ^a   Heutte, Natacha ^a   Delozier, Thierry ^b   Hardouin, Agnes ^b   Bardet, Stéphane ^b  

^a Nuclear Medicine Department   (France)

^b CENTRE FRANÇOIS BACLESSE   (France)

Author keywords

Breast cancer; CA 15 3; Doubling time; Fluorodeoxyglucose; Kinetics; PET; Recurrence

Indexed keywords

CA 15-3 ANTIGEN; FLUORODEOXYGLUCOSE F 18;

AGED; ARTICLE; BREAST CANCER; CALCULATION; CANCER RECURRENCE; CLINICAL ARTICLE; DIAGNOSTIC PROCEDURE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; NUCLEAR MEDICINE; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; CA-15-3 ANTIGEN; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE ENHANCEMENT; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PATIENT SELECTION; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 34247553913     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32801a3e90     Document Type: Article

References (14)

1. De La Lande B, Hacene K, Floiras JL, Alatrakchi N, Pichon MF. Prognostic value of CA 15.3 kinetics for metastatic breast cancer. Int J Biol Markers 2002; 17:231-238.
2. Cheung KL, Graves CR, Robertson JF. Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat Rev 2000; 26:91-102.
3. Bidart JM, Thuillier F, Augereau C, Chalas J, Daver A, Jacob N, et al. Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clin Chem 1999; 45:1695-1707.
4. Belhocine T, Spaepen K, Dusart M, Castaigne C, Muylle K, Bourgeois P, et al. 18FDG PET in oncology: the best and the worst [Review]. Int J Oncol 2006; 28:1249-1261.
5. Crippa F, Gerali A, Alessi A, Agresti R, Bombardieri E. FDG-PET for axillary lymph node staging in primary breast cancer. Eur J Nucl Med Mol Imaging 2004; 31(suppl 1):S97-S102.
6. Lind P, Igerc I, Beyer T, Reinprecht P, Hausegger K. Advantages and limitations of FDG PET in the follow-up of breast cancer. Eur J Nucl Med Mol Imaging 2004; 31(suppl 1):S125-S134.
7. Liu CS, Shen YY, Lin CC, Yen RF, Kao CH. Clinical impact of [(18)F]FDG-PET in patients with suspected recurrent breast cancer based on asymptomatically elevated tumor marker serum levels: a preliminary report. Jpn J Clin Oncol 2002; 32:244-247.
8. Suarez M, Perez-Castejon MJ, Jimenez A, Domper M, Ruiz G, Montz R, Carreras JL, et al. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers. Q J Nucl Med 2002; 46:113-121.
9. Pecking AP, Mechelany-Corone C, Bertrand-Kermorgant F, Alberini JL, Floiras JL, Goupil A, Pichon MF, et al. Detection of occult disease in breast cancer using fluorodeoxyglucose camera-based positron emission tomography. Clin Breast Cancer 2001; 2:229-234.
10. 18F]FDG in recurrent breast cancer: diagnostic performances, clinical impact and relevance of induced changes in management. Eur J Nucl Med Mol Imaging 2004; 31:179-188.
11. Avril N, Rose CA, Schelling M, Dose J, Kuhn W, Bense S, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 2000; 18:3495-3502.
12. Svatek RS, Shulman M, Choudhary PK, Benaim E. Critical analysis of prostate-specific antigen doubling time calculation methodology. Cancer 2006; 106:1047-1053.
13. Rodrigues NA, Chen MH, Catalona WJ, Roehl KA, Richie JP, D'Amico AV. Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancer. Cancer 2006; 107:514-520.
14. D'Amico AV, Kantoff P, Loffredo M, Renshaw AA, Loffredo B, Chen MH. Predictors of mortality after prostate-specific antigen failure. Int J Radiat Oncol Biol Phys 2006; 65:656-660.